Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Carcinoma, Non-Small-Cell Lung|Melanoma|Nasopharyngeal Carcinoma|Microsatellite Stable Colorectal Cancer|Triple Negative Breast Cancer
Interventions: DRUG: DKY709|DRUG: PDR001
Sponsor: Novartis Pharmaceuticals